RARE Ultragenyx
Company Analysis
Latest News
Ultragenyx Posts Its Best Quarter Ever, But Can a Still-Unprofitable Biotech Turn a Revenue Beat Into a Real Turnaround?
Shares of Ultragenyx Pharmaceutical shifted sharply higher after the rare-disease drugmaker delivered a blowout second quarter that caught Wall Street off...
Ultragenyx Posts Its Best Quarter Ever, But Can a Still-Unprofitable Biotech Turn a Revenue Beat Into a Real Turnaround?
Shares of Ultragenyx Pharmaceutical shifted sharply higher after the rare-disease drugmaker delivered a blowout second quarter that caught Wall Street off...
🟢 Ultragenyx is trading 4.6% up today after record Q2 revenue beat
Ultragenyx is trading 4.6% up now at $26.07 after investors continued reacting to its August 4 earnings release and record second-quarter revenue. -...
🔴 Ultragenyx is trading 4.1% down today on post-earnings profit-taking
Ultragenyx is trading 4.1% down at $24.77 today as the stock undergoes a typical post-earnings reversal following yesterday's significant rally. • The company...
🟢 Ultragenyx is trading 4.1% up today after record Q2 revenue and earnings beat
Ultragenyx is trading 4.1% up at $25.57 after reporting record second-quarter revenue that significantly exceeded Wall Street expectations. • The company...
🟢 Ultragenyx is trading 6.4% up today after record Q2 revenue and earnings beat
Ultragenyx is trading 6.4% up at $27.47 in pre-market sessions after reporting record second-quarter revenue and a narrower-than-expected net loss per...
🟢 Ultragenyx is trading 6.4% up today after reporting record Q2 revenue and a narrowed net loss
Ultragenyx is trading at $27.46 (6.4% up) after reporting record second-quarter revenue of $214 million, which exceeded consensus estimates and narrowed its...
Ultragenyx reports record second quarter revenue of $214M, beating estimates and reaffirming its FY2026 outlook.
Ultragenyx Pharmaceutical announced record revenue for its second quarter, surpassing analyst expectations on both revenue and earnings per share. The company...
🟢 Ultragenyx is trading 4.1% up today ahead of Q2 earnings and pipeline updates
Ultragenyx is trading 4.1% up at $26.04 as investors position ahead of the company’s second-quarter 2026 earnings report scheduled for August 04, 2026. •...
Ultragenyx Q2 2026 Earnings Preview: What Analysts Expect on August 04, 2026
Analysts anticipate a Q2 2026 loss of $1.27 per share on revenue of $182.5 million, with the current stock price of $52.42 significantly trailing the consensus...
🔴 Ultragenyx is trading 4.5% down today amid a broader biotech sector pullback
Ultragenyx is trading 4.5% down today at $24.86 following a broader pullback in the biotechnology sector. • The move appears driven by risk-off sentiment...
🟢 Ultragenyx is trading 4.3% up today amid broad market strength and biotech sector gains
Ultragenyx is trading at $26.07 (up 4.3%) amid a broad risk-on move in U.S. equities and strength in biotech peers. • The stock appears to be rebounding from...
🔴 Ultragenyx is trading 4.2% down today tracking broader biotech and macro weakness
Ultragenyx is trading at $24.88 (-4.23%) as the stock faces pressure amid a broader biotech risk-off tone and general market weakness. • No fresh...
🔴 Ultragenyx is trading 4.2% down today with no clear company-specific catalyst
Ultragenyx is trading 4.2% down today at $25.92 as the stock faces individual pressure despite a supportive backdrop for the broader biotech industry. • No...
🔴 Ultragenyx is trading 4.4% down today, extending a multi-day slide as the biotech sector weakens
Ultragenyx is trading 4.4% down today at $32.58, extending a multi-day slide triggered by disappointing trial developments and cautious sentiment surrounding...
🔴 Ultragenyx is trading 4.25% down today amid biotech volatility and trial disappointment
Ultragenyx is trading 4.25% down today at $33.14 as the stock continues to slide amid broader biotech volatility and a lack of new company-specific...
🔴 RARE is trading 4.1% down today with no clear company-specific catalyst
RARE is trading 4.1% down at $34.41 today with no fresh company-specific news or major catalysts identified. • The decline follows a strong 6.4% gain during...
🟢 RARE is trading 4.6% up today despite a lack of fresh company-specific news
RARE is trading at $35.26 (up 4.6%) on a generally weak broader market, though no clear company-specific catalyst has been identified for the move. • The...
🟢 RARE makes sharp 10.2% jump
RARE is trading at $33.81, up 10.2% versus the comparison close of $30.68 during regular trading. This is a price-movement alert; no separate company-specific...
🟢 RARE extends move to 6.8% up
RARE is trading at $32.77, up 6.8% versus the comparison close of $30.68 during regular trading. This is a price-movement alert; no separate company-specific...